What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Seock-Ah Im mainly investigates Internal medicine, Oncology, Cancer, Chemotherapy and Breast cancer.
Seock-Ah Im combines subjects such as Gastroenterology and Surgery with his study of Internal medicine.
His study in Oncology is interdisciplinary in nature, drawing from both Randomized controlled trial, Pathology, Palbociclib, Fulvestrant and Survival analysis.
His work deals with themes such as Tyrosine kinase, Cancer research, Lung cancer and Pharmacology, which intersect with Cancer.
His Chemotherapy study combines topics from a wide range of disciplines, such as Neoadjuvant therapy, Retrospective cohort study, Radiology, Colorectal cancer and Triple-negative breast cancer.
His Breast cancer study integrates concerns from other disciplines, such as Surgical oncology and Docetaxel.
His most cited work include:
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (1664 citations)
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial (1283 citations)
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (1004 citations)
What are the main themes of his work throughout his whole career to date?
Seock-Ah Im mainly focuses on Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer.
He has included themes like Gastroenterology and Surgery in his Internal medicine study.
The various areas that Seock-Ah Im examines in his Oncology study include Gemcitabine, Hormone receptor, Docetaxel and Pathology.
His studies deal with areas such as Surgical oncology and Radiation therapy as well as Breast cancer.
His Cancer research is multidisciplinary, incorporating elements of Stage, Retrospective cohort study, Cancer research and Pharmacology.
His Metastatic breast cancer research is multidisciplinary, relying on both Taxane, Clinical endpoint and Capecitabine.
He most often published in these fields:
- Internal medicine (93.72%)
- Oncology (71.90%)
- Breast cancer (46.93%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (93.72%)
- Oncology (71.90%)
- Breast cancer (46.93%)
In recent papers he was focusing on the following fields of study:
Seock-Ah Im focuses on Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer.
When carried out as part of a general Internal medicine research project, his work on Chemotherapy, Trastuzumab, Phases of clinical research and Adverse effect is frequently linked to work in In patient, therefore connecting diverse disciplines of study.
Seock-Ah Im interconnects Pembrolizumab, Capecitabine, Hormone receptor, Palbociclib and Gemcitabine in the investigation of issues within Oncology.
He has researched Breast cancer in several fields, including Interim analysis, Cancer research, Clinical endpoint and Hazard ratio.
His study on Metastatic breast cancer also encompasses disciplines like
- Biomarker, which have a strong connection to Bone metastasis,
- Olaparib most often made with reference to Tolerability.
His work deals with themes such as Clinical trial, Seroconversion and Vaccination, which intersect with Cancer.
Between 2018 and 2021, his most popular works were:
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer (239 citations)
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer (222 citations)
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. (126 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Clinical trial.
His study involves Trastuzumab, Pertuzumab, Phases of clinical research, Letrozole and Progression-free survival, a branch of Internal medicine.
His Oncology research includes elements of Pembrolizumab, Chemotherapy, Randomized controlled trial, Hormone receptor and Palbociclib.
His studies in Breast cancer integrate themes in fields like Interim analysis, Regimen, Biopsy and Gemcitabine.
His Metastatic breast cancer study incorporates themes from Biomarker, Lung cancer, Adverse effect and ERBB3.
In his work, Seroconversion and Programmed cell death is strongly intertwined with Cancer, which is a subfield of Clinical trial.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
